Your browser is no longer supported. Please, upgrade your browser.
SHPG Shire plc daily Stock Chart
Shire plc
Index- P/E22.13 EPS (ttm)7.94 Insider Own0.10% Shs Outstand306.52M Perf Week-2.62%
Market Cap53.82B Forward P/E11.15 EPS next Y15.75 Insider Trans0.00% Shs Float299.32M Perf Month-0.79%
Income2.42B PEG4.10 EPS next Q3.77 Inst Own20.90% Short Float0.64% Perf Quarter2.89%
Sales15.70B P/S3.43 EPS this Y160.00% Inst Trans1.47% Short Ratio1.96 Perf Half Y3.93%
Book/sh122.40 P/B1.43 EPS next Y4.18% ROA7.20% Target Price199.30 Perf Year21.41%
Cash/sh0.68 P/C259.88 EPS next 5Y5.40% ROE13.00% 52W Range123.73 - 182.47 Perf YTD13.20%
Dividend1.06 P/FCF15.45 EPS past 5Y7.50% ROI4.30% 52W High-3.77% Beta1.01
Dividend %0.60% Quick Ratio0.50 Sales past 5Y27.30% Gross Margin70.30% 52W Low41.91% ATR3.02
Employees23044 Current Ratio0.90 Sales Q/Q4.70% Oper. Margin21.20% RSI (14)44.66 Volatility1.28% 1.49%
OptionableYes Debt/Eq0.41 EPS Q/Q-3.50% Profit Margin30.60% Rel Volume1.47 Prev Close178.99
ShortableYes LT Debt/Eq0.30 EarningsNov 01 BMO Payout5.50% Avg Volume976.96K Price175.59
Recom1.80 SMA20-1.08% SMA50-0.37% SMA2008.55% Volume1,440,075 Change-1.90%
Sep-07-18Downgrade Berenberg Buy → Hold
Sep-04-18Downgrade Bernstein Outperform → Mkt Perform
May-11-18Resumed Kepler Buy
Feb-20-18Downgrade JP Morgan Overweight → Neutral
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $201 → $181
Feb-14-18Upgrade Bernstein Mkt Perform → Outperform
Dec-20-17Downgrade Liberum Buy → Hold
Nov-14-17Upgrade Liberum Hold → Buy
Oct-19-17Initiated FBR & Co. Buy $201
Oct-11-17Reiterated RBC Capital Mkts Outperform $213
Aug-17-17Initiated Evercore ISI Outperform $196
Jun-16-17Initiated Cantor Fitzgerald Overweight $222
Jun-09-17Reiterated Jefferies Buy $239 → $216
Jun-01-17Downgrade Liberum Buy → Hold
May-26-17Downgrade Bernstein Outperform → Mkt Perform
May-19-17Downgrade HSBC Securities Hold → Reduce
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
Nov-16-18 04:19AM  [$$] Takeda dissident investors make last push to block Shire deal Financial Times
02:00AM  Shire Announces New HELP Study(TM) Data for Lanadelumab in HAE at 2018 ACAAI Annual Scientific Meeting GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-15-18 08:21PM  Takeda Pharmaceutical Company Limited -- Moody's assigns A2 to Takeda's proposed notes; places rating under review for downgrade Moody's
Nov-14-18 04:15PM  David Abrams Buys Shire, Boosts Lithia Motors
12:11PM  David Abrams Buys 3 Stocks in 3rd Quarter
08:02AM  Shire's Filing Accepted by FDA for Gattex's Label Expansion Zacks
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-13-18 05:20PM  Daniel Loeb Purchases 7 Stocks in 3rd Quarter
07:00AM  U.S. FDA Accepts for Filing Shires Supplemental New Drug Application for GATTEX® (teduglutide ) for Children with Short Bowel Syndrome GlobeNewswire
Nov-12-18 01:39PM  Takeda's Shire takeover to bring $963 million fee bonanza Reuters
04:00AM  Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Reuters
03:59AM  Takeda sets vote date, aims to close $62 billion Shire deal on January 8 Reuters
02:54AM  [$$] Takeda sets date for shareholder vote on £46bn Shire deal Financial Times
02:00AM  Rule 2.9 Announcement GlobeNewswire
02:00AM  Publication of Scheme Document GlobeNewswire
Nov-11-18 11:32PM  [$$] Takeda and Shire to pay almost $1bn in deal fees and expenses Financial Times
Nov-09-18 01:11PM  Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources Reuters
12:15PM  Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources Reuters
10:31AM  Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3 Zacks
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-08-18 09:11PM  Takeda Pharmaceutical Company Limited -- Moody's assigns A2 to Takeda's proposed notes; places rating under review for downgrade Moody's
12:36PM  Takeda Hires Banks for Euro Bonds to Finance Shire Takeover Bloomberg
Nov-07-18 02:58PM  [$$] Shire Spinout Mirum Pharmaceuticals Launches With $120 Million The Wall Street Journal
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-06-18 11:10PM  Edited Transcript of SHP.L earnings conference call or presentation 1-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-05-18 10:13AM  Takeda CEO confident of investor backing for $62 billion Shire deal Reuters
Nov-02-18 06:36PM  Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3 Zacks
03:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-01-18 12:15PM  Director/PDMR Shareholding GlobeNewswire
09:59AM  Shire: 3Q Earnings Snapshot Associated Press
08:49AM  [$$] Shire 3Q Net Profit Falls on Taxes The Wall Street Journal
08:00AM  3rd Quarter Results GlobeNewswire
07:00AM  Total voting rights GlobeNewswire
03:00AM  Rule 2.9 Announcement GlobeNewswire
03:00AM  Form 8 (DD) - Flemming Ornskov GlobeNewswire
Oct-30-18 03:00AM  Rule 2.9 announcement GlobeNewswire
Oct-29-18 03:28AM  Takeda proposes sale of Shire drug to gain European approval Reuters
Oct-26-18 02:00AM  Rule 2.9 announcement GlobeNewswire
Oct-25-18 07:00AM  Shire Files Submission for U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-24-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-23-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-22-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-19-18 08:29AM  Shire's drug for rare swelling disorder wins European panel green light Reuters
08:10AM  Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
08:00AM  Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-18-18 05:44PM  FDA Advisory Committee Recommends Approval of Shires Prucalopride (SHP555) for Chronic Idiopathic Constipation GlobeNewswire
07:00AM  Notice of Results GlobeNewswire
04:33AM  Takeda gets Japanese approval for $62 billion Shire purchase Reuters
03:40AM  Takeda gets Japan's approval for $62 billion Shire purchase Reuters
02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-16-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-15-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-12-18 04:00AM  Irish bioscience company opens new $1.2 billion Georgia plant American City Business Journals
02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-11-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-10-18 10:35AM  J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study Zacks
02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-09-18 09:15PM  Seven & i Holdings Co., Ltd. -- Moody's: Rated Japanese corporates' cash to stay high, but pace of growth to slow Moody's
Oct-08-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-05-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-04-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-03-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Oct-02-18 09:30AM  Director/PDMR Shareholding GlobeNewswire
02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Oct-01-18 07:00AM  Director/PDMR Shareholding GlobeNewswire
06:45AM  Form 8 (DD) - Susan Kilsby GlobeNewswire
06:45AM  Form 8 (DD) - Steven Gillis GlobeNewswire
06:45AM  Form 8 (DD) - Sara Mathew GlobeNewswire
06:45AM  Form 8 (DD) - Olivier Bohuon GlobeNewswire
06:45AM  Form 8 (DD) - Ian Clark GlobeNewswire
06:45AM  Form 8 (DD) - Gail Fosler GlobeNewswire
06:45AM  Form 8 (DD) - David Ginsburg GlobeNewswire
06:45AM  Form 8 (DD) - Albert Stroucken GlobeNewswire
05:30AM  Total voting rights GlobeNewswire
02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Sep-28-18 12:35PM  Takeda's $62 billion Shire bid faces November 6 EU antitrust deadline Reuters
11:52AM  Takeda's $62 billion Shire bid faces Nov. 6 EU antitrust deadline Reuters
02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Sep-27-18 09:12AM  Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap Zacks
Sep-26-18 02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Sep-24-18 05:00PM  Japan Is Asias M&A King While China Gets the Pushback Bloomberg
02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Sep-23-18 05:29AM  Takeda Shareholder `Skeptical' About Shire Takeover, Sunday Times Says Bloomberg
Sep-21-18 01:56PM  4 Stocks John Paulson and Paul Tudor Jones Agree On
09:45AM  Is Shire (SHPG) a Suitable Stock for Value Investors Now? Zacks
08:51AM  The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding Benzinga
02:00AM  Shire Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan GlobeNewswire
02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Sep-20-18 07:00AM  Health Canada has authorized TAKHZYRO(TM) (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema (HAE) attacks GlobeNewswire
02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Sep-19-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Sep-18-18 02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Sep-17-18 10:08AM  Company News For Sep 17, 2018 Zacks
02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Sep-14-18 07:23AM  Takeda gets China's approval for $62 billion Shire purchase Reuters
03:55AM  Takeda gets China's approval for $62 billion Shire purchase Reuters
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.